Cerity Partners LLC grew its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 65.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,090 shares of the medical research company's stock after purchasing an additional 10,761 shares during the period. Cerity Partners LLC's holdings in Exact Sciences were worth $1,541,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Tidal Investments LLC grew its holdings in shares of Exact Sciences by 172.2% during the 3rd quarter. Tidal Investments LLC now owns 34,275 shares of the medical research company's stock worth $2,335,000 after acquiring an additional 21,683 shares during the period. Synovus Financial Corp purchased a new stake in Exact Sciences in the third quarter worth $490,000. American Trust bought a new position in Exact Sciences in the third quarter worth $229,000. GAMMA Investing LLC lifted its position in Exact Sciences by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,674 shares of the medical research company's stock valued at $206,000 after buying an additional 828 shares during the period. Finally, Modus Advisors LLC bought a new stake in shares of Exact Sciences during the 4th quarter valued at $43,000. Hedge funds and other institutional investors own 88.82% of the company's stock.
Wall Street Analysts Forecast Growth
EXAS has been the topic of a number of recent research reports. Mizuho initiated coverage on shares of Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective on the stock. Bank of America cut their price target on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th. Benchmark reiterated a "buy" rating and set a $65.00 price objective on shares of Exact Sciences in a research note on Monday, January 13th. Royal Bank of Canada assumed coverage on Exact Sciences in a research note on Thursday, March 13th. They issued a "sector perform" rating and a $52.00 target price on the stock. Finally, William Blair restated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $69.25.
Read Our Latest Analysis on EXAS
Exact Sciences Stock Performance
Shares of EXAS traded up $1.59 during trading hours on Wednesday, hitting $45.74. The stock had a trading volume of 418,627 shares, compared to its average volume of 2,604,245. Exact Sciences Co. has a 12 month low of $39.97 and a 12 month high of $72.83. The stock has a fifty day moving average price of $45.60 and a 200 day moving average price of $54.62. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The firm has a market capitalization of $8.50 billion, a PE ratio of -8.21 and a beta of 1.14.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current year.
About Exact Sciences
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
See Also
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
